Business Context and Reporting Period
The filing is The Beauty Health Company’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022. The company, traded as SKIN, develops, manufactures, markets and sells aesthetic technologies and products, primarily through its Hydrafacial platform, delivery systems and consumables. The filing entity differs from the metadata description “Skinhealth Systems Inc.”
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Net sales | $88.8 million | $68.1 million | $267.7 million | $182.2 million |
| Gross profit | $61.6 million | $46.1 million | $185.2 million | $125.1 million |
| Gross margin | 69.3% | 67.6% | 69.2% | 68.6% |
| Operating loss | $4.1 million | $5.5 million | $20.5 million | $29.4 million |
| Net income (loss) | $0.1 million | $(215.1) million | $40.6 million | $(357.8) million |
| Adjusted EBITDA | $16.5 million | $5.8 million | $31.4 million | $24.2 million |
| Adjusted EBITDA margin | 18.6% | 8.5% | 11.7% | 13.3% |
- Q3 net sales increased 30.3%; nine-month sales increased 47.0% year over year.
- Delivery Systems revenue increased 35.7% in Q3 and 60.7% for the nine-month period. Consumables revenue increased 24.2% and 31.4%, respectively.
- The company sold 1,860 Delivery Systems units in Q3, with management attributing demand in part to the Syndeo delivery system.
- Cash and cash equivalents were $684.2 million at September 30, 2022, compared with $901.9 million at December 31, 2021.
- Operating cash flow was negative $101.2 million for the first nine months, primarily reflecting inventory investment of $69.3 million and increased accounts receivable of $40.6 million.
- Investing cash outflow was $16.0 million, including $9.9 million of property and equipment spending and $4.7 million of capitalized software.
- Financing cash outflow was $102.8 million, primarily due to the $100.0 million accelerated share repurchase.
- The company had $750.0 million principal amount of 1.25% convertible senior notes due 2026, carried net at $733.1 million. Estimated fair value was approximately $603.8 million.
- The $50.0 million revolving credit facility was undrawn, and the company reported compliance with its financial and other covenants.
- Current assets were $892.4 million versus current liabilities of $76.4 million at September 30, 2022.
Material Changes Versus the Prior Comparable Period
- Profitability improved substantially from the prior-year period, although the Q3 operating result remained negative. The improvement in reported net income was heavily influenced by non-cash warrant fair-value movements.
- Q3 2022 included $4.3 million of income from the change in fair value of warrant liabilities, compared with $199.3 million of expense in Q3 2021. For the nine-month periods, the corresponding amounts were $71.5 million of income in 2022 versus $271.3 million of expense in 2021.
- Gross margin improved by 170 basis points in Q3 and 60 basis points for the nine-month period, primarily from volume-related fixed-cost leverage and stronger realized Delivery Systems pricing.
- Adjusted EBITDA rose in Q3 but declined for the nine-month period as a percentage of sales, reflecting increased investments in selling and marketing, personnel, travel, training and promotional programs.
- Selling and marketing expense increased 30.6% in Q3 and 62.4% for the nine-month period. Stock-based compensation increased to $20.9 million for the nine-month period from $8.6 million.
- Inventory increased from $35.3 million at December 31, 2021 to $101.7 million at September 30, 2022, in part to support the Syndeo launch.
- On September 27, 2022, the company entered into a $100.0 million accelerated share repurchase agreement and initially retired approximately 7.7 million shares. Shares outstanding declined to 143.2 million from 150.6 million at year-end 2021.
Guidance, Outlook, Risks and Unusual Items
- Management expects capital expenditures of up to $20.0 million for full-year 2022 and believes available liquidity is sufficient for anticipated operating requirements for at least the next twelve months.
- The filing does not provide specific revenue or earnings guidance.
- Management expects inflationary pressure on raw materials, shipping and labor costs to continue into the fourth quarter of 2022. Potential mitigations include price increases and accepting revenue in U.S. dollars or local currencies, but these actions may not fully offset the impact.
- Global component and raw-material shortages and transportation delays reduced order fill rates, particularly in parts of Europe and Asia. The company expected supply-chain challenges to continue through the remainder of fiscal 2022.
- COVID-19 restrictions, including China’s zero-tolerance policies, caused intermittent store closures, travel restrictions and uneven consumer traffic. Management expects recovery to remain gradual and non-linear.
- Foreign-exchange movements, a stronger U.S. dollar, higher interest rates, inflation, recession risk and industry consolidation may adversely affect demand, margins and reported results. The company stopped selling and shipping products to its Russian distributor following Russia’s invasion of Ukraine.
- The company recorded a $2.0 million write-off primarily related to the discontinued Glow & Go pilot program, as well as $4.7 million of losses on disposal of long-lived assets during the nine-month period.
- The company disclosed continuing material weaknesses in disclosure controls and internal control over financial reporting, primarily involving insufficient accounting resources, segregation of duties and formal risk assessment. Remediation efforts include hiring, consultants, additional review procedures and information-technology controls.
- The company reported no material pending legal proceedings and no material off-balance-sheet arrangements.
Investor Verification Points
- Verify the sustainability of revenue growth and Syndeo demand after accounting for supply-chain constraints, customer payment plans and foreign-exchange effects.
- Assess whether gross-margin gains can persist despite inflation, shipping costs, labor costs, component shortages and currency pressure.
- Separate recurring operating performance from non-GAAP adjustments and volatile warrant-liability fair-value gains.
- Monitor cash conversion, particularly the elevated inventory and accounts receivable balances and continued negative operating cash flow.
- Review the $750.0 million convertible notes, 2026 maturity, conversion terms, potential dilution and capped-call protection.
- Track final settlement of the accelerated share repurchase, remaining authorization and the effect on cash, share count and diluted earnings per share.
- Confirm remediation and testing of the disclosed material weaknesses in internal control over financial reporting.